ANGLE plc announced the appointment of Daniel Costin Danila, MD, as a Scientific Advisor to the company with immediate effect. Dr. Danila is a leader in the development and adoption of CTCs as predictive biomarkers to help clinicians select appropriate treatments. He is an assistant attending physician at Memorial Hospital Cancer Center in New York as well as an instructor with the Weill Cornell Medical College.

Most recently, Dr. Danila served as the principal investigator (PI) for "Circulating Tumor Cells as Biomarkers for Patients with Metastatic Prostate Cancer: Developing Assays for Androgen Receptor Signaling Pathway", which focused on analysing CTCs from patients with metastatic prostate cancer for molecular biomarkers predictive of tumor sensitivity to targeted treatments.